Vertex Pharmaceuticals

VRTXintermediary

Vertex Pharmaceuticals dominates the cystic fibrosis market with Trikafta and is expanding into gene editing (Casgevy for sickle cell), non-opioid pain (suzetrigine), and kidney disease. Its CF franchise generates massive cash flow to fund pipeline diversification.

⇄ Compare

Produk & Pendapatan

Pangsa Pendapatan Produk

Komposisi Pendapatan ($11.2B)

Data statis (memuat keuangan langsung…)

Cystic Fibrosis (Trikafta) (78%)

Gene Therapy (Casgevy) (8%)

Other Products & Collaborations (14%)

Komposisi segmen dan pelanggan utama

Detail produk

Trikafta / Kaftrio65%

Triple-combination CFTR modulator for cystic fibrosis — standard of care

Casgevy (exa-cel)8%

CRISPR-based gene therapy for sickle cell disease and beta-thalassemia

Pain Pipeline (VX-548, suzetrigine)10%

Non-opioid NaV1.8 pain inhibitor for acute and neuropathic pain

Hubungan Rantai Pasok

Pesaing

Eli Lilly and Company

Pain therapeutics pipeline

Dampak: Competing in non-opioid pain

Regeneron Pharmaceuticals

Gene editing and rare disease

Dampak: Competing in genetic medicine

Pfizer Inc.

Gene therapy and rare disease

Dampak: Limited overlap

Konteks makro dan pasar

제약 / 바이오Berita sektor

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

Katalis mendatang

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

Berita terkini

Memuat berita...

Analisis AI

Klik "Dapatkan Analisis AI" untuk analisis rantai pasok Vertex Pharmaceuticals.

Info Perusahaan

Kantor Pusat

Boston, Massachusetts, USA

Didirikan

1989

Karyawan

10,400+

Situs Web

vrtx.com

Gambaran umum sektor — 제약 / 바이오

Berita sektor